Dengue Moment
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
The World Health Organization (WHO) has donated 2,160 doses of Ebola trial vaccine to Uganda to evaluate the efficacy of the vaccine in combating the virus which in the recent outbreak has killed a health worker in Kampala, the country's capital.
Indonesia is developing a new Tuberculosis (TB) vaccine to strengthen the fight against TB, which has claimed an average of 150,000 lives annually.
The landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
Specifically, the team compared the immune responses in people who were protected against CMV infection after receiving the older vaccine.
With markets opening and restrictions getting lifted, nothing seems to stop Nepalis from organising jatras, rallies and all kinds of indoor and outdoor gatherings that draw huge crowds.
The study found that a fourth dose can reduce the possibilities of symptomatic infection, hospitalisation, serious illness and mortality among the elders, Clalit said, Xinhua news agnecy reported.
“We administered 147 vaccines on Monday, a marginal 12 per cent increase over yesterday. Encouragingly, there has been a 20 per cent rise in number of precaution doses in the 18-59 category. The numbers should further increase as the news spreads about the booster in this age group,”
Approximately 35 per cent of the world’s population has not received at least one dose, while more than 42 per cent of the world’s population has not been fully vaccinated. One can easily observe the inequitable distribution of vaccines between the Global North and the Global South.
The statement further said that Covovax is the fourth vaccine to receive EUA from the DCGI for use among adolescents 12 and older.
